Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2483267 | 1.00 | SLC2A1 (0.55) | SLC2A1KCNH2 | |
| SCHEMBL2485629 | 0.94 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL2509566 | 0.92 | SLC2A1 (0.66) | SLC2A1KCNH2 | |
| SCHEMBL2505146 | 0.92 | SLC2A1 (0.66) | SLC2A1KCNH2 | |
| SCHEMBL2500818 | 0.89 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2503540 | 0.86 | KCNH2 (0.56) | SLC2A1KCNH2 | |
| SCHEMBL2508203 | 0.86 | KCNH2 (0.62) | SLC2A1KCNH2 | |
| SCHEMBL2482432 | 0.86 | KCNH2 (0.62) | SLC2A1KCNH2 | |
| SCHEMBL586207 | 0.82 | KCNH2 (0.53) | SLC2A1KCNH2 | |
| SCHEMBL586385 | 0.81 | KCNH2 (0.65) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376497-B1 | 5-AMINO-2-(1-HYDROXY-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8211890-B2 | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives | Actelion Pharmaceuticals (CH) | 2012-07-03 | — | — | US | claimed |
| US-20110245259-A1 | 5-Amino-2-(1-Hydroxy-Ethyl)-Tetrahydropyran Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-06 | — | — | US | claimed |
| EP-2376497-B1 | 5-AMINO-2-(1-HYDROXY-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8211890-B2 | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives | Actelion Pharmaceuticals (CH) | 2012-07-03 | — | — | US | disclosed |
| EP-2376497-A1 | 5-AMINO-2-(1-HYDROXY-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245259-A1 | 5-Amino-2-(1-Hydroxy-Ethyl)-Tetrahydropyran Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-06 | — | — | US | disclosed |
| WO-2010067332-A1 | 5-AMINO-2-(1-HYDROXY-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245259-A1 | 5-Amino-2-(1-Hydroxy-Ethyl)-Tetrahydropyran Derivatives | CD2, CD22, DRD3 | SLC2A1 3352/4885KCNH2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.